389650
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.
389650 (389650) - Net Assets
Latest net assets as of September 2025: ₩46.25 Billion KRW
Based on the latest financial reports, 389650 (389650) has net assets worth ₩46.25 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩58.09 Billion) and total liabilities (₩11.84 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩46.25 Billion |
| % of Total Assets | 79.61% |
| Annual Growth Rate | 107.12% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
389650 - Net Assets Trend (2021–2024)
This chart illustrates how 389650's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 389650 (2021–2024)
The table below shows the annual net assets of 389650 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩45.19 Billion | +865.83% |
| 2023-12-31 | ₩-5.90 Billion | -2224.69% |
| 2022-12-31 | ₩-253.84 Million | -104.99% |
| 2021-12-31 | ₩5.08 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to 389650's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1050832407000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩4.04 Billion | 8.95% |
| Other Components | ₩111.33 Billion | 246.35% |
| Total Equity | ₩45.19 Billion | 100.00% |
389650 Competitors by Market Cap
The table below lists competitors of 389650 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADVA Optical Networking SE
PINK:ADVOF
|
$243.68 Million |
|
Tristel PLC
PINK:TSNLF
|
$243.69 Million |
|
338840
KQ:338840
|
$243.70 Million |
|
Runben Biotechnology Co Ltd Ordinary Shares - Class A
SHG:603193
|
$243.86 Million |
|
Heba Fastighets AB Series B
LSE:0GNV
|
$243.62 Million |
|
Black Box Limited
NSE:BBOX
|
$243.59 Million |
|
STHREE PLC LS -01
F:S8T
|
$243.47 Million |
|
Mennica Polska S.A.
WAR:MNC
|
$243.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 389650's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,900,999,750 to 45,191,393,970, a change of 51,092,393,720.
- Net income of 2,859,558,460 contributed positively to equity growth.
- Share repurchases of 28,919,590,980 reduced equity.
- New share issuances of 28,919,590,980 increased equity.
- Other factors increased equity by 48,232,835,260.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.86 Billion | +6.33% |
| Share Repurchases | ₩28.92 Billion | -63.99% |
| Share Issuances | ₩28.92 Billion | +63.99% |
| Other Changes | ₩48.23 Billion | +106.73% |
| Total Change | ₩- | % |
Book Value vs Market Value Analysis
This analysis compares 389650's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 111.21x to 12.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩634.82 | ₩70600.00 | x |
| 2022-12-31 | ₩-31.70 | ₩70600.00 | x |
| 2023-12-31 | ₩-736.88 | ₩70600.00 | x |
| 2024-12-31 | ₩5588.37 | ₩70600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 389650 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.33%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.97%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.30x
- Recent ROE (6.33%) is above the historical average (-80.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -327.42% | -734.13% | 0.06x | 7.81x | ₩-17.15 Billion |
| 2022 | 0.00% | -205.07% | 0.09x | 0.00x | ₩-5.71 Billion |
| 2023 | 0.00% | -154.06% | 0.16x | 0.00x | ₩-6.93 Billion |
| 2024 | 6.33% | 29.97% | 0.16x | 1.30x | ₩-1.66 Billion |
Industry Comparison
This section compares 389650's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 389650 (389650) | ₩46.25 Billion | -327.42% | 0.26x | $243.63 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |